12 January 2018 - The changing regulatory landscape brings new challenges to health technology assessment. Marketing authorisations are being granted as the evidence base evolves to facilitate timely patient access to promising health technologies.
Changes to the Cancer Drugs Fund (CDF) have resulted in a managed access fund for cancer medicines in England. NICE can now recommend a treatment for use within the CDF if there is plausible potential to satisfy the criteria for routine use in the National Health Service at its current price, but the evidence is not robust enough and associated with significant uncertainty.
The first treatment recommended for use within the new CDF was osimertinib mesylate for non-small-cell lung cancer.